Radhika Rao, MD
Psychiatry · Saint Louis, MONPI 1952485708
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 1,117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,117 payments — averaging $14.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $8K from 31 others
What the payments were for
- Food & beverage$16,30899%
- Education$1431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$115
- ABILIFY ASIMTUFII$102
- ABILIFY MAINTENA$102
How this compares
$16,451 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 47 | $409,085 |
| Invega SustennaPaliperidone Palmitate | 64 | $194,682 |
| VraylarCariprazine Hcl | 94 | $137,758 |
| Invega TrinzaPaliperidone Palmitate | 11 | $113,123 |
| RexultiBrexpiprazole | 59 | $93,360 |
| AustedoDeutetrabenazine | 13 | $81,331 |
| Chlorpromazine Hcl | 84 | $68,415 |
| CaplytaLumateperone Tosylate | 42 | $64,298 |
| UzedyRisperidone | 29 | $57,032 |
| Lurasidone Hcl | 138 | $55,300 |
| TrintellixVortioxetine Hydrobromide | 66 | $40,014 |
| Abilify MaintenaAripiprazole | 15 | $35,949 |
| Divalproex Sodium ErDivalproex Sodium | 274 | $29,704 |
| BelsomraSuvorexant | 52 | $28,916 |
| FanaptIloperidone | 13 | $27,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,437 | $409,08547 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,091 | $307,80575 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $909 | $138,36342 claims |
| AbbVieVraylar | $1,603 | $137,75894 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,878 | $129,30974 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,162 | $64,29842 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,079 | $48,77989 claims |
| MerckBelsomra | $146 | $28,91652 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $338 | $27,60413 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $57 | $19,86213 claims |
| Axsome Therapeutics, Inc.Auvelity | $776 | $14,31412 claims |
| Orexo US, Inc.Zubsolv | $77 | $6,03614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.